Daiichi Jitsugyo Co (8059) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
31 Jul, 2026Executive summary
Net sales for the three months ended June 30, 2026, declined 16.7% year-over-year to ¥41,232 million, with operating profit down 57.7% to ¥1,057 million and ordinary profit down 48.1% to ¥1,292 million.
Profit attributable to owners of parent was ¥1,762 million, a slight increase from ¥1,745 million in the prior year period.
Comprehensive income surged 124.3% year-over-year to ¥4,504 million, driven by significant gains in other comprehensive income.
Financial highlights
Gross profit decreased to ¥7,550 million from ¥8,609 million year-over-year.
Basic earnings per share for the quarter was ¥55.26, up from ¥54.74 in the prior year.
Total assets increased to ¥184,296 million as of June 30, 2026, from ¥175,639 million at March 31, 2026.
Net assets rose to ¥92,475 million, with an equity ratio of 50.1%.
Outlook and guidance
Full-year net sales forecast is ¥210,000 million, down 4.2% year-over-year.
Operating profit is projected at ¥12,000 million (down 12.4%), ordinary profit at ¥12,400 million (down 13.6%), and profit attributable to owners of parent at ¥9,400 million (down 5.5%).
Basic earnings per share for the year is forecast at ¥294.79.
Latest events from Daiichi Jitsugyo Co
- Record profits and cash flow achieved despite lower sales; outlook remains cautious.8059
Q4 202615 May 2026 - Record Q3 profits and strong segment growth support an upwardly revised full-year outlook.8059
Q3 20264 Feb 2026 - Record Q2 sales and profits led to upward revisions in full-year forecasts and dividends.8059
Q2 20267 Nov 2025 - Record-high sales and profit, improved equity ratio, and strong full-year outlook.8059
Q2 20259 Sep 2025 - Record Q3 sales and profits, stock split, and strong growth across all segments.8059
Q3 20259 Sep 2025 - Record sales and profits, strong overseas growth, and a conservative outlook for next year.8059
Q4 20259 Sep 2025 - Record Q1 sales and profits driven by Healthcare and Automobile, but outlook is slightly cautious.8059
Q1 20269 Sep 2025 - Strong sales and profit growth, with robust outlook and improved equity ratio.8059
Q1 20259 Sep 2025